44.
45. 46. 47. 48.
49. 50.
51. 52.
53. 54.
55. 56.
59. 60.
61. 62. 63.
64. 65.
66. 67. 68. 69.
58. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14: 309-17.
Benchimol EI, To T, Griffiths AM et al. Outcomes of pediatric inflammatory bowel disease:
THE IMPACT OF INFLAMMATORY BOWEL DISEASE IN CANADA 90
Nugent Z, Blanchard JF, Bernstein CN. A population-based study of health-care resource use among infliximab users. Am J Gastroenterol 2010; 105: 2009-16.
Canadian Institute for Health Information [CIHI] (2010). National Health Expenditure Trends: 1975-2010. Canadian Institute for Health Information.
www.cihi.ca.
Third-party payers an average of $19,000 to $22,000 a year per patient, according to the drug’s developer, Centocor Inc (Jenssen in Canada).
Bernstein CN, Longobardi T, Finlayson G et al. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis 2011;
IMS Brogan Inc. Pharmastat Prescription Database. Ottawa, 2012. Data on file.
Sandborn WJ, Rutgeerts P, Feagan BG et al. Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from Act 1 and Act 2. Gut 2007; 56 (Suppl III): A26.
Jewell DP, Satsangi J, Lobo A et al. Infliximab use in Crohn’s disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17: 47-52.
Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002; 35: 151-6.
Lichtenstein GR, Yan S, Bala M et al. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. AM J Gastroenterol 2003; 91-6.
57. Feagan BG, Vreeland MB, Larson LR et al. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol 2000; 95: 1955-60.
Gibson PR, Weston AR, Shann A et al. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn’s disease. J Gastroenterol Hepatol 2007; 22: 1306-12.
Bassi A, Dodd S, Williamson P et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-8.
Hilsden RJ, Verhoef MJ, Best A et al. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol 2003; 3: 10.
Silverstein MD, Loftus EV, Sandborn WJ et al. Clinical course and costs of car for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterol 1999; 117: 49-57.
Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007; 21: 507-11.
Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroent and Hep 2008; 6: 41-5.
Hoie O, Schouten LJ, Wolters FL et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort ten years after diagnosis. Gut 2007; 56: 497-503.
Jess T, Gamborg M, Matzen P et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterology 2005; 100: 2724-9.
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 2—6; 23: 1097-104.
Jess T, Riis L, Vind I et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481-9.
Hutfless SM, Weng X, Liu L et al. Mortality by medication use among patients with inflammatory bowel disease. Gastroenterology 2007; 133: 1779-86.
Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn’s disease. Aliment Pharmacol Ther 2007; 25: 861-70.
Crohn’s and Colitis Australia. The economic costs of Crohn’s disease and ulcerative colitis. June, 2007.
www.crohnsandcolitis.com.au.
Benchimol EI, Fortinsky KJ, Gozdyra P et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423-439.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96